Listed by the USPTO as MOORE, JOHN DAVID
Tech Center 1700 • Art Units: 1638 1644 1687 1799
This examiner grants 61% of resolved cases
MOORE, JOHN DAVID examines in Tech Center 1700 and Art Unit 1638. The record contains 54 resolved cases, with a 61.1% allowance rate and a 28.3% interview lift. The median time to allowance is 1277 days. The listed companies are Translate Bio Inc., Sana Biotechnology Inc., and Fujifilm Holdings Corporation. The listed firms are NOVICK, KIM & LEE, PLLC, dba NKL Law, SUGHRUE MION, PLLC, and BIRCH STEWART KOLASCH & BIRCH, LLP.
The allowance rate is more than twice the interview lift, so the overall outcome measure and the interview measure tell different parts of the prosecution story. The 54 resolved cases provide a larger base than a single-digit record, while the 1277-day median signals that successful prosecution may require time. Counsel can use the listed entities to identify subject-matter and drafting patterns in related files. The figures support targeted review of claim amendments, interviews, and final resolution paths rather than reliance on the allowance rate alone.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19028665 | PRODUCTION METHOD OF MESENCHYMAL STEM CELL | Non-Final OA | FUJIFILM Corporation |
| 18472847 | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF HUMAN CELLULAR IMMUNE SYSTEM | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18537479 | REAGENTS AND METHODS FOR PRODUCING ARTERIAL HEMOGENIC ENDOTHELIUM, HEMATOPOIETIC PROGENITORS, AND LYMPHOID CELLS THEREBY | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17930810 | ADAPTATION OF PLATFORM HOSTS TO IGF- MEDIA | Non-Final OA | Amgen Inc. |
| 18858543 | METHOD FOR CONVERTING HUMAN SOMATIC CELLS INTO PROLIFERATIVE NEURAL STEM CELLS | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18880108 | ESTABLISHMENT OF IMMORTALIZED ERYTHROID PROGENITOR CELL LINE WITH SUPERIOR CAPABILITY OF DIFFERENTIATING INTO RED BLOOD CELLS BY USING GENETIC OVEREXPRESSION COMBINATION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) |
| 18241669 | METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY | Final Rejection | Sanofi |
| 18290436 | CARTILAGE MODEL AS A SUBSTITUTE FOR ANIMAL MODELS AND METHODS FOR EVALUATING EFFECTIVENESS OR TOXICITY OF DRUGS USING THE SAME | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18376459 | METHOD FOR PREPARING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR, COMPOSITION PREPARED BY THE METHOD, AND USE OF COMPOSITION FOR TREATING ARTHRITIS | Non-Final OA | GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD. |
| 18800672 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 18692497 | Screening Method Using Brown Adipocytes | Final Rejection | Kyoto Prefectural Public University Corporation |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | Non-Final OA | Sana Biotechnology, Inc. |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | Non-Final OA | Sana Biotechnology, Inc. |
| 18289361 | MANUFACTURING METHOD OF MEMORY T CELLS | Non-Final OA | Yasuhito Tokumoto |
| 17906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | Non-Final OA | BioNTech Cell & Gene Therapies GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy61.1% of resolved applications examined by John David Moore were allowed (54 resolved cases), compared with 49.3% across Art Unit 1638 over the last five years.
This examiner's interview lift is +28.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by John David Moore took 1,277 days on average from filing to allowance.
John David Moore examines applications in Art Unit 1638 in Tech Center 1700 (Chemistry & Materials).